retatrutide phase 3 trial results VisualAbstract: reduces body weight by 17.5% in patients with obesity Retatrutide Phase 3 Results: Trials,
Description
Monthly cash costs vary by brand, dose, formulation, and whether you use an FDA-approved product or a compounded alternative
Diabetes Care 2017
That difference highlights the biggest unknown about this pill: real-world adherence
Retatrutide becomes the right conversation in 2028, when it's actually available, and specifically for patients who tried tirzepatide with insufficient results or who have severe obesity requiring maximum pharmacological intervention
Unlimited support from our dedicated medical team throughout your journey
It is worth noting that the landscape for licensed weight-management medicines in the UK is evolving
